Drug Trial Radar · NCT07694765
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
Conditions
- Malignant Tumors
Interventions
LM-364 for injectionDrug
Q3W, Intravenous Drip
TislelizumabDrug
Q3W, Intravenous Drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT)Time frame: 78 weeks
- Incidence of Treatment-Emergent Adverse Events (AEs)Time frame: 78 weeks
- Incidence of serious adverse events (SAEs)Time frame: 78 weeks
- Temperature (Celsius)Time frame: 78 weeks
- Pulse in BPM(Beat per Minute)Time frame: 78 weeks
- Blood Pressure in mmHgTime frame: 78 weeks
- Weight in KgTime frame: 78 weeks
- Height in centimetersTime frame: 78 weeks
- Blood Routine examination -> Complete Blood CountTime frame: 78 weeks
- Urine Routine examination ->UrinalysisTime frame: 78 weeks
- Blood Biochemistry test -> Electrolytes and Metabolic ParametersTime frame: 78 weeks
- Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT),Time frame: 78 weeks
- Pregnancy testTime frame: 78 weeks
- Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
- Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
- Objective Response Rate (ORR)Time frame: 130 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Macquarie University
North Ryde, New South Wales, Australia
Cancer Care Wollongong Hospital
Wollongong, New South Wales, Australia
Icon Cancer Centre South Brisbane
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.